Erratum to “The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma” Lung Cancer 132 (June) (2019) 36–38

The publisher regrets that the Conflict of Interests statements provided by the author were not added as supplementary items. Please see below a summary statement of the conflicts of interest for this manuscript:
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Erratum Source Type: research

Related Links:

LncRNA AWPPH participates in the metastasis of non-small cell lung cancer by upregulating TGF-β1 expression. Oncol Lett. 2019 Oct;18(4):4246-4252 Authors: Huo Y, Li A, Wang Z Abstract Long non-coding RNA (lncRNA) AWPPH is a characterized oncogenic lncRNA in hepatocellular carcinoma and bladder cancer. The aim of the present study was to investigate the potential involvement of AWPPH in non-small cell lung cancer (NSCLC). Expression of AWPPH in lung biopsy tissues and serum of both healthy controls and patients with NSCLC with different tumor sizes, and with and without distant tumor metastasis was...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Lung cancer is the leading cause of cancer mortality among men and second to breast cancer among women. Up to 85 –90% of cases are attributed to cigarette smoking. Around 85% of patients are diagnosed with non-small cell lung carcinoma (NSCLC), with approximately 80% diagnosed at stages III and IV. Median survival of patients treated with numerous combination chemotherapies has been around 1 year, with ver y few patients surviving more than 3 years after diagnosis. Targeted therapies have changed the prognosis for a select group of patients who harbor a tumor-specific oncogene that could be targeted.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and unique subtype of primary non-small cell lung cancer (NSCLC) that histologically resembles undifferentiated nasopharyngeal carcinoma (NPC) [1]. It is recognized to be etiologically associated with Epstein-Barr virus (EBV) infection in endemic area [2]. Currently, pulmonary LELC is classified as “other and unclassified carcinomas” according to the 2015 World Health Organization Classification Lung Tumors [3]. Over the past decades, less than 600 cases have been reported in the literature.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionThis study demonstrates that neoantigen-specific T cells can be detected in peripheral blood in non-small cell lung cancer (NSCLC) patients during anti-PD-L1 therapy. Patients with an objective response had an enrichment of neoantigen-reactive T cells and these cells showed a phenotype that differed from patients without a response. These findings suggest the ex vivo identification, characterization, and longitudinal follow-up of rare tumor-specific differentiated effector neoantigen-specific T cells may be useful in predicting response to checkpoint blockade.Trial registrationPOPLAR trialNCT01903993.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
AbstractPatients with non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) have shown benefit from anti-PD-1 therapies. However, not all patients experience tumor shrinkage, durable responses or prolonged survival, demonstrating the need to find response markers. In blood samples from NSCLC and RCC patients obtained before and after anti-PD-1 treatment, we studied leukocytes by complete blood cell count, lymphocyte subsets using flow cytometry and plasma concentration of nine soluble mediators, in order to find predictive biomarkers of response and to study changes produced after anti-PD-1 therapy. In baseline...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Authors: Yang M, Chen H, Zhou L, Chen K, Su F Abstract Non-small cell lung cancer (NSCLC) is a highly malignant type of cancer with a poor 5-year survival rate. The development of prognostic biomarkers and novel drug targets are required in order to improve the survival for NSCLC patients. Signal transducer and activator of transcription (STAT) proteins are cytoplasmic transcription factors known to play key roles in many cellular biological processes. However, the roles of STAT family members in the development and progression of NSCLC have not yet been apparently determined. Our study investigated the roles of ST...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
OTUD7B, a multifunctional deubiquitinylase, plays an essential role in inflammation and proliferation signals. However, its function in lung cancer remains largely unknown. The aim of this study was to evaluate the prognostic significance of OTUD7B in patients with lung adenocarcinoma and squamous carcinoma and to characterize its molecular mechanisms in lung cancer progression and metastasis. Two tissue microarrays containing 150 pairs of lung squamous carcinoma and matched adjacent non-cancer tissues, and one tissue microarray containing 75 pairs of lung adenocarcinoma and adjacent non-cancer tissues were included, and i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsPD-1 inhibitors are now widely used in a multitude of cancer types including melanoma, advanced non-small cell lung cancer, metastatic renal cell carcinoma, and Hodgkin lymphoma amongst others. While these agents are often well tolerated, they are associated with a unique profile of immune-related toxicities that can cause significant morbidity and mortality. Education of both patients and healthcare providers is essential for diagnosis and treatment of these adverse events early in their course. This case highlights the uncommon but potentially serious PD-1-associated toxicity of myopathy and rhabdomyolysis alo...
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS SUMO1P3 expression was an independent indicator of reduced RFS in patients with LUAD. PMID: 31489957 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
ConclusionsThese findings support the use of immunohistological subtyping of NSCLC biopsy specimens to select patient-appropriate treatments.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer